Daily AI-curated articles on clinical trials, FDA updates, and pharmaceutical insights.
FDA approves tividenofusp alfa-eknm (Avlayah) for neurologic manifestations of Hunter syndrome, marking a significant milestone in MPS II treatment.
Cardinal Health recalls Webcol alcohol prep pads due to Paenibacillus phoenicis contamination, raising critical sterile procedure concerns for clinical research sites.
New clinical trial in Gainesville, FL investigates one-time minimally invasive procedure for patients with uncontrolled blood pressure despite triple therapy.
Daiichi Sankyo and AstraZeneca's Enhertu receives additional regulatory approvals in Japan, marking significant progress for the ADC therapy in expanding clinical applications.
The FDA announces a public meeting to gather feedback on its Commissioner's National Priority Voucher pilot program, signaling potential changes to drug development incentives.
Rhythm Pharmaceuticals' Imcivree receives FDA approval for acquired hypothalamic obesity, marking first treatment option for this challenging condition.
FDA's new draft guidance on New Approach Methodologies (NAMs) promises to accelerate drug development while reducing animal testing through human-centric validation methods.
Fierce Pharma's annual drug naming tournament highlights critical considerations for clinical researchers in pharmaceutical branding and nomenclature.
